The Shanghai company is financing multicenter trials, regulatory approval and manufacturing capacity for its implantable brain-computer interface platform.
NeuroXess, the Shanghai-based brain-computer interface company also known as BrainTiger Technology, has raised RMB 700 million, approximately $105 million, in a Series B financing round.
The investment was jointly led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital, with participation from additional medical technology, semiconductor and institutional investors. The company's original announcement is dated October 28, 2026.
Founded by CEO and chief scientist Tao Hu, NeuroXess is developing a system designed to interpret neural activity and allow users with severe motor impairments to interact with digital devices and their environment.
An Implanted, Wireless Interface
NeuroXess describes its platform as fully implanted, wireless and capable of multiple functions, including movement and speech decoding. Its approach aims to avoid externally connected hardware while allowing patients to perform everyday activities without cumbersome connections.
The company said it had completed 65 clinical cases and began a registration-stage clinical trial at Huashan Hospital, affiliated with Fudan University, on July 7. It plans to work with hospitals across China to establish safety and effectiveness evidence for medical registration.
The new capital will support those trials, regulatory submissions, next-generation devices and exploration of AI-assisted interfaces. NeuroXess also describes plans for a large manufacturing facility, though planned production capacity should not be confused with current output.
From Laboratory Demonstrations to Medical Evidence
Interest in brain-computer interfaces is rising globally, with companies pursuing different approaches to implantability, decoding and patient applications. However, the transition from impressive laboratory demonstrations to an approved medical product is long and demanding.
Implanted devices must establish both clinical benefit and acceptable safety risks. Manufacturing consistency, surgical workflow, durability, data protection and long-term support all matter. Progress in a limited group of patients does not guarantee broad effectiveness.
NeuroXess says it aims to scale clinical and commercial operations over the next two years. That remains an ambition rather than approval or proof of widespread clinical use.
The financing signals growing institutional support for China's brain-computer interface industry. The decisive milestone will be successfully completing the regulatory pathway and demonstrating repeatable patient outcomes outside tightly controlled trials.
Sources: NeuroXess official announcement · Dealroom